Science & Enterprise subscription

Follow us on Twitter

  • Make me wanna shout ... #BillsMafia https://t.co/iF1vhKHXtu
    about 2 hours ago
  • First of two podcasts with experiences of news photographers in the insurrection. Thanks @cherissmay for sharing yo… https://t.co/aCjPD6ct84
    about 18 hours ago
  • Half or more of American adults express negative opinions about the way Covid-19 vaccines are distributed, accordin… https://t.co/9l2SUpW85u
    about 24 hours ago
  • New post on Science and Enterprise: Infographic – US Public Down on Vaccine Rollout https://t.co/vegz3ihvIO #Science #Business
    about 24 hours ago
  • We've written several times about Lander and his work, including companies he founded. ... Biden to Elevate Science… https://t.co/rWVGTa1gPL
    about 1 day ago

Please share Science & Enterprise

Stem Cell Therapy Licensed for Genetic Eye Disease

Red-blue-green eye

A biotechnology company is licensing its stem cell treatments for retinitis pigmentosa, an inherited eye disease, in a deal valued at $252 million. . . . → Read More: Stem Cell Therapy Licensed for Genetic Eye Disease

Blood Cancers Respond to Cord Blood Cells

Katy Rezvani

A small-scale clinical trial shows most patients with two blood-related cancers safely respond to immune system cells derived from umbilical cord blood. . . . → Read More: Blood Cancers Respond to Cord Blood Cells

Infographic – China Closes R&D Funding Gap

R&D spending 2017

A new report from National Science Foundation shows China now ranks a close second to the U.S. in total research and development investments. . . . → Read More: Infographic – China Closes R&D Funding Gap

Synthetic Bio Cancer Immunotherapy Company Acquired

Natural killer cell

A biotechnology company creating synthetic proteins that invoke the immune system to fight cancer is being acquired by drug maker Astellas Pharma. . . . → Read More: Synthetic Bio Cancer Immunotherapy Company Acquired

Trial Shows Nanotech Drug Induces Gluten Tolerance

bread and rolls

Results from a clinical trial show an experimental treatment encourages immune-system tolerance of gluten, preventing intestinal damage from celiac disease. . . . → Read More: Trial Shows Nanotech Drug Induces Gluten Tolerance

Migraine Drug Developer Raises $82.5M in IPO

NASDAQ share price display

A developer of a drug for migraine formulated as a dry powder and given as a nasal spray is raising $82.5 million in its initial public offering of common stock. . . . → Read More: Migraine Drug Developer Raises $82.5M in IPO

Sumitomo Dainippon, Biotechs in $3B Acquisition Deal

Laptops on a table

Japanese pharmaceutical company Sumitomo Dainippon agreed to acquire five biotechnology companies and gain an equity stake in the Roivant Sciences group. . . . → Read More: Sumitomo Dainippon, Biotechs in $3B Acquisition Deal

Hearing Loss Cell Therapy Licensed in $625M Deal

Man with headphones

A biotechnology company developing regenerative treatments for various disorders is licensing its lead therapy candidate for hearing loss to Astellas Pharma. . . . → Read More: Hearing Loss Cell Therapy Licensed in $625M Deal

Stem Cell Start-Up Raises $250M in Venture Funds

T-cell lymphocyte

A company begun last year to create cancer therapies from banked, off-the-shelf stem cells is raising $250 million in its first round of venture financing. . . . → Read More: Stem Cell Start-Up Raises $250M in Venture Funds

Genetic Risk Analysis Shows Ethnic Bias

DNA puzzle

Techniques analyzing data from across the genome that reveal risks of diseases, better predict disorders in the main ethnicity of the population studied than other ethnic groups. . . . → Read More: Genetic Risk Analysis Shows Ethnic Bias